Antibe’s Clinical Advisory Board (“CAB”) assists the Company in designing the clinical development program of its portfolio of drug candidates for pain and inflammation.
Dr. J. Carter Thorne
Dr. Thorne is Chief of the Division of Rheumatology and Director of The Arthritis Program at Southlake Regional Health Centre in Newmarket, Canada.
Dr. Thorne holds a Fellowship with the Royal College of Physicians in Internal Medicine and Rheumatology FRCP(C), is a Fellow at the American College of Physicians and American College of Rheumatology FACP, and sits on numerous national and international steering and scientific committees identifying and disseminating outcomes and best practices in the management of arthritis.
Dr. Francis Chan
Dr. Chan is a Professor of Medicine at the Chinese University of Hong Kong (CUHK). In February 2014, he was appointed Dean of Medicine. Dr. Chan obtained his degree in medicine in 1988, and received a medical doctorate in 1998, both while attending CUHK. The latter included research studies conducted at the University of Calgary, in Alberta, Canada. Dr. Chan has received numerous international awards for his research, including The David Y. Graham Lecturer award in 2005 from the American College of Gastroenterology.
Dr. Chan has been the lead investigator of numerous large clinical trials, including several focusing on Celebrex, one of the most widely used nonsteroidal anti-inflammatory drugs.
Dr. Angel Lanas
Dr. Lanas is a Professor of Medicine and Chief of Gastroenterology at the University Hospital, Institute of Health Sciences of Aragon, Zaragoza, Spain.
Dr. Lanas obtained his medical degree at the University of Zaragoza in 1979. He completed postgraduate training in internal medicine at Zaragoza’s University Hospital and was awarded his doctor of medicine degree 1984. Since 1987, Dr. Lanas’ research has been largely focused on the adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the gastrointestinal tract.
Dr. Lanas has lead multiple pioneering medical research studies and clinical trials and has drawn attention to the significant ulceration and bleeding that NSAIDs can cause in the small intestine, and the fact that such damage typically goes undiagnosed.
Dr. James Scheiman
Dr. Scheiman is the Director of Endoscopic Research and Advanced Endoscopy Training Program at the University of Michigan. He also serves as the Associate Editor for the American Journal of Gastroenterology and previously was the Associate Editor for ‘Gastrointestinal Endoscopy’.
Dr. Scheiman is an authority on the effects of aspirin and other NSAIDs on the GI tract. He has played a leading role in establishing guidelines on reducing the risks of bleeding with these drugs. He leads an active research program focusing on acid related disorders such as peptic ulcer disease and gastroesophageal reflux disease; on the early diagnosis of gastrointestinal malignancies, particularly pancreatic cancer; and on the economics of health care.
Dr Scheiman received his BS and MD from the University of Michigan, and completed his post-graduate clinical and research training at the University of Michigan Affiliated Hospitals in Ann Arbor, Michigan.